NEW YORK--(BUSINESS WIRE)--
Retrophin, Inc. (OTCQB:RTRX) announced today that management will host a
conference call and webcast, to discuss its operational and financial
results for the period ended September 30, 2013, on Monday, November 18,
2013 at 4:30pm EST. The Company filed its form 10-Q on November 13, 2013.
|
Access information:
|
|
|
|
|
Date:
|
|
|
Monday, November 18, 2013
|
|
Time:
|
|
|
4:30 pm EST
|
|
Dial-in numbers:
|
|
|
877-703-6109 (U.S. and Canada) or 857-244-7308
|
|
Conference ID number:
|
|
|
63839921
|
|
Live web cast:
|
|
|
www.retrophin.com,
under "Investor Relations"
|
|
|
|
|
|
The teleconference replay will be available from 8:30 pm EST on Monday,
November 18, 2013 through 11:59 pm EST on Monday, November 25, 2013. The
replay number is 888-286-8010 (U.S. and Canada) or 617-801-6888,
confirmation code 59828006.
About Retrophin
Retrophin is a pharmaceutical company focused on the discovery and
development of drugs for the treatment of debilitating and often
life-threatening diseases for which there are currently no viable
patient options. The Company is currently focused on several
catastrophic diseases affecting children, including Focal Segmental
Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated
Neurodegeneration (PKAN) and Duchenne Muscular Dystrophy. Retrophin's
lead compound, RE-021, is scheduled to begin enrollment in a potentially
pivotal Phase 2 clinical trial for the treatment of FSGS during 2013.
For additional information, please visit www.retrophin.com.
Retrophin, Inc.
Marc Panoff, 646-564-3671
CFO
marc@retrophin.com
or
Investors
Rx
Communications Group
Paula Schwartz, 917-322-2216
pschwartz@rxir.com
Source: Retrophin, Inc.
News Provided by Acquire Media